According to the Zhitong Finance App, Kehua Biology (002022.SZ) issued an announcement. Recently, the company received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the State Drug Administration, involving the product “Hepatitis B virus nucleic acid test kit (PCR-fluorescence probe method)”, which is used to quantitatively detect hepatitis B virus nucleic acid (HBVDNA) in human serum or plasma samples.
科华生物(002022.SZ)：“乙型肝炎病毒核酸测定试剂盒(PCR-荧光探针法)”获得医疗器械注册证
Kehua Biotech (002022.SZ): “Hepatitis B virus nucleic acid test kit (PCR-fluorescence probe method)” obtained medical device registration certificate
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.